For the year ending 2025-12-31, ORGO made $564,169K in revenue. $20,022K in net income. Net profit margin of 3.55%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 564,169 | 482,043 | ||
| Write down of capitalized internal-use software costs | - | 3,959 | ||
| Cost of goods sold | - | 115,741 | ||
| Impairment of property and construction (note 8) | - | 18,842 | ||
| Cost of goods sold | 137,522 | - | ||
| Gross profit | - | 366,302 | ||
| Selling, general and administrative | 326,236 | 294,513 | ||
| Research and development | 44,542 | 50,271 | ||
| Write-down to fair value for asset held for sale | 11,175 | - | ||
| Total operating expenses | 519,475 | 367,585 | ||
| Income (loss) from operations | 44,694 | -1,283 | ||
| Interest income (expense), net | -2,281 | 1,544 | ||
| Other income (expense), net | -5 | 20 | ||
| Total other income (expense), net | 2,276 | -1,524 | ||
| Net income (loss) before income taxes | 46,970 | -2,807 | ||
| Income tax benefit (expense) | 9,938 | -3,668 | ||
| Net income (loss) and comprehensive income (loss) | 37,032 | 861 | ||
| Accretion of redeemable convertible preferred stock to redemption value | 540 | 412 | ||
| Cumulative dividend on redeemable convertible preferred stock | 10,830 | 1,386 | ||
| Undistributed earnings allocated to participating redeemable convertible preferred stock | 5,640 | - | ||
| Net income (loss) attributable to common stockholders - basic | 20,022 | -937 | ||
| Basic EPS | 0.16 | -0.01 | ||
| Diluted EPS | 0.15 | -0.01 | ||
| Basic Average Shares | 126,738,136 | 131,673,278 | ||
| Diluted Average Shares | 130,248,412 | 131,673,278 | ||
Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. (ORGO)